Dr. K, 45, was an ophthalmologist with a private practice. One of Dr. K’s patients, Mrs. M, 72, was having a small mass on her eyelid removed and Dr. K was using an outpatient surgical facility and one of its nurses.
Recent reports have demonstrated a link between acute kidney injury (AKI) and chronic kidney disease (CKD). Individuals with AKI are more likely to have CKD and eventually progress to end-stage renal disease.
There has recently been a tremendous increase in emphasis on quality and patient safety within American medicine. Much of this is due to an improved ability to look at and evaluate results from large numbers of patients and determine “best practices” shown to improve outcomes.
The renal function preservation clinic for patients with kidney cancer represents a new multidisciplinary approach to an old problem.
Physicians are indeed spending less face time with patients, according to studies and to what doctors have told me in conversation. One consequence of this could be less time to educate patients about their illness.
Many obese dialysis patients are asked to lose weight to qualify for kidney transplantation. If such usual weight reduction programs as dieting or anti-appetite medications do not work, some patients will be introduced to more aggressive interventions such as bariatric surgery.
Prostate cancer (PCa) is more likely to be diagnosed in men who have been hospitalized for clinical benign prostatic hyperplasia (BPH) or undergone surgery for the condition, according to a Danish study.
A recent analysis of data from 1,255 diabetic hemodialysis (HD) patients found that low levels of homoarginine are a strong risk factor for sudden cardiac death (SCD) and death due to heart failure in this population.
In a long-term randomized trial of 150 kidney transplant recipients with a median follow-up of eight years post-transplant, those undergoing immunosuppressive therapy with tacrolimus/mycophenolate mofetil (MMF) experienced significantly less frequent acute rejection (12%) than those treated with tacrolimus/sirolimus (30%) or cyclosporine/sirolimus (28%).
Testing for the genetic anomaly TMPRSS2:ERG in conjunction with use prostate cancer antigen 3 (PCA3) is better at predicting the presence of prostate cancer (PCa) than either marker alone, according to a report in Science Translational Medicine.
